• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Mutating Haematopoietic Stem Cells May Cure Sickle Cell Disease

November 16, 2016

Stem Cell Research

Sickle cell disease and β-thalassaemia are caused by mutations in the β -globin gene. Previous studies have shown that transplants of normal β-globin genes into haematopoietic stem cells (HSC) may cure the disease; however, this process is considered inefficient.  New advances recently published in Nature point towards an approach that may improve the efficiency of this intervention.  Researchers were able to correct human HSCs that carry the mutation responsible for sickle cell disease in mice.  Briefly, normal β-globin genes were delivered with an adeno-associated viral vector delivery system into purified human HSCs with the sickle cell gene, and the CRISPR/Cas-9 gene editing system was used to prompt homologous recombination of the normal gene into the target HSCs. New purifying techniques using fluorescence-activated cell sorting or magnetic bead enrichment allowed researchers to collect populations of cells with more than 85% of the normal β-globin gene integrations. These new advances in methodology may help lead to cures for hematological diseases.

Reference:

Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, Pavel-Dinu M, Saxena N, Wilkens AB, Mantri S, Uchida N, Hendel A, Narla A, Majeti R, Weinberg KI, Porteus MH. CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells. Nature 2016.

Filed Under

  • Cell Therapy
  • News

Recommended

  • Whole Blood Transfusions on the Battlefield

  • Plasma Transfused During Transport to Hospital Saves Lives in Trauma Patients

  • Donor Deferral of MSM May Inappropriately Conflate Group Membership with Individual Risk

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Personalized Prediction Model of Prophylactic Platelet Transfusions for Preterm Infants

  • Caffeine in Donor Blood Reduces Quality of Stored RBCs

  • Ferritin Levels Needed to Assess Hemoglobin Recovery after Blood Donation

  • Transfusion of RBCs from Cord Blood May Protect Low-Weight Preterm Infants from Severe Retinopathy

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley